-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer's new crown oral drug Paxlovid did not enter health insurance - this is the most important news
on the last day of medical insurance negotiations in 2022.
Today, the National Health Insurance Administration announced the participation of new crown treatment drugs in the negotiation of the 2022 medical insurance drug list, among the new crown oral drugs, azvudine tablets and lung cleansing detoxification granules were successfully negotiated, and Paxlovid was unsuccessful
due to the high quotation of the manufacturer Pfizer Investment Co.
, Ltd.
Before the release of this news, rumors about "Paxlovid price dropped to 700 yuan" were widely circulated on the Internet, causing heated discussions in the market
.
Health care negotiations have been particularly confidential this year, with unwitting over-the-counter rumors
.
In addition to the rumor of 700 yuan, rumors about the timing and length of Paxlovid's negotiations are also in doubt
.
Qian Yun, vice president and head of market access at Pfizer Biopharma Group China, appeared yesterday, and she entered the venue alone at 8:30 a.
m.
to negotiate and did not appear until 1:20 p.
m
.
After appearing, Qian Yun asked reporters questions, his expression was serious and did not respond
.
The outside world speculates that the negotiation product that Qian Yun is responsible for is Paxlovid
.
At one o'clock this afternoon, an insider in the health care negotiations pulled the box out of the conference center
.
He revealed that the much-watched new crown oral drug Paxlovid was negotiated this morning, not yesterday
.
According to on-site observations, there are more than 10 enterprises participating in medical insurance negotiations this morning, including Chia Tai Tianqing, Fangsheng Pharmaceutical, Haosen, Junshi, etc.
, which shows that the negotiation varieties include proprietary Chinese medicines and innovative drugs
.
Today's negotiations are relatively fast, with an average of 5 companies appearing every hour between 9 and 12 o'clock
.
But there are also companies that
take longer to negotiate.
Hausen's negotiators said it was only an hour of talks, while the companies that came out after Hausen said it was "very difficult and a little long.
"
According to the preliminary review catalog, there are five products negotiated by Hausen
.
And what does the failure of the much-anticipated Paxlovid (hereinafter referred to as P drug) mean in this negotiation? Is the spring of domestic new crown oral medicine coming?
And what does the failure of the much-anticipated Paxlovid (hereinafter referred to as P drug) mean in this negotiation? Is the spring of domestic new crown oral medicine coming?
After the 2022 medical insurance negotiations, there are no cars parked in front of the National People's Congress Conference Center
-01-
-01-P drug generic drugs on the agenda?
P drug generic drugs on the agenda?The price reduction of Pfizer P drugs is not new
.
As early as December 28 last year, according to media reports, the drug's medical insurance paid the price from
2300 yuan/box was lowered to 1890 yuan/box
.
As a result, public expectations for it to be insured have grown
.
Recently, some media reported that some domestic pharmaceutical companies are expected to be authorized to produce and sell generic drugs of P drugs, and the terms of the license transaction may be finalized as soon as January 22 (the Spring Festival of the lunar calendar).
The report revealed that at a meeting at the end of last month, companies including Zhejiang Huahai Pharmaceutical and CSPC Pharmaceutical Group participated to discuss the preparations needed to produce generic drugs of P drugs
.
It is worth noting that in August last year, Huahai signed an agreement with Pfizer to only produce P drugs
for use in the mainland.
In addition, the report also said that potential candidates including Huahai and CSPC have been working in recent weeks
"Bioequivalence test", which is a necessary work before the approval of generic drugs, mainly examines the absorption speed and degree of the corresponding original drug, as long as it is 80%-125% of the original drug, it can be assumed that it has the same
efficacy as the original drug.
The two companies could submit test results
later this month.
"Even if the cost of generic drugs is high, there are profit margins
for these companies.
" An industry insider said
.
Last March, 35 generic drug manufacturers around the world, including five domestic pharmaceutical companies, agreed to produce cheap versions of Paxlovid
for 95 poorer countries through licensing arrangements with the United Nations-backed Medicines Patent Pool (MPP).
But the license doesn't allow the companies to sell generic versions
of Paxlovid in China.
Recently, there have been frequent information on the market about selling P drugs at high prices, such as scalpers even speculating their price to 50,000 yuan, which is more than
20 times its original price.
-02-
-02-The spring of domestic oral medicine is coming?
The spring of domestic oral medicine is coming?Now that P drugs have not been included in the medical insurance catalogue through negotiation, according to the official information of the Medical Insurance Bureau, medical insurance will pay temporarily until March 31
, 2023.
If you look at the reason given by the Medical Insurance Bureau - "due to the high quotation of the manufacturer Pfizer Investment Co.
, Ltd.
failed to succeed", the price became the reason for its failure, which also means that the Medical Insurance Bureau has a very
low tolerance for the high price of new crown oral drugs.
"This actually shows that the health insurance bureau's attitude is very firm, that is, the price of new crown oral drugs should not be too high
.
" There are industry insiders analysis
.
.
" There are industry insiders analysis
.
But Pfizer Pfizer, which first grabbed the window period, has quickly made enough money - this is the luck and cruelty of the field of drug research and development
.
Market information is constantly changing, and the meaning that time is money is becoming more and more obvious
.
The former earns a lot of money, and the latter is likely to lose
anything.
In fact, this attitude also coincides with a notice issued by the Health Insurance Bureau two days ago
.
On January 6, the National Health Insurance Administration issued a notice from the Office of the National Medical Security Administration
Notice
of the "Guidelines for the Formation of Prices of Novel Covid Treatment Drugs (Trial)".
At that time, "P medicine is still not discussed" became a question
hanging in the minds of many people.
.
The notice states that "from January 1, 2023, the national drug administration has approved the marketing (including conditional listing) of new crown treatment drugs"
.
This clearly means that the pricing of new crown oral drugs on the market after that cannot be too high
.
A clear signal is that the pricing of new crown oral drugs on the market in the future will be reduced, the accessibility will become stronger, and ordinary people will be able to buy such drugs
at low prices.
The notice also said that in order to adapt to the new situation and new tasks of the prevention and control of the new crown virus infection, we will support the diversified supply of
new crown treatment drugs around "maintaining health and preventing severe diseases".
"Diversified supply, multiple measures, this means you can you
up
。 "At the door of the medical insurance negotiation venue, someone is interpreting
"Many" means that domestic and foreign companies can do both, and vaccines and oral drugs are carried out at the same time, "This situation is definitely not good for Pfizer
.
" Sure enough, Pfizer P drugs, which have not reduced enough prices, have not been covered by medical insurance
despite being robbed.
However, there is also the fact that the price guidance measures of the Health Insurance Bureau are not blindly price reductions, but also consider the cost and clinical value
of enterprises.
Including "raw material costs, R&D expenses, period expenses", and also fully consider "innovation" and "economy"
.
Among them, economy is one of the important pricing principles, "when the cost calculation is significantly higher than the economic evaluation result, the pricing needs to be based on the economic evaluation result
.
" ”
of enterprises.
Including "raw material costs, R&D expenses, period expenses", and also fully consider "innovation" and "economy"
.
According to the notice, if the "sales expense rate, management expense rate and financial expense ratio of the initial offering quotation are more than 10 percentage points higher than the average level of pharmaceutical enterprises listed on the Science and Technology Innovation Board in the past three years, the applicant will be accepted to actively guide the applicant to adjust its quotation strategy
.
" An industry insider said that pharmaceutical companies need to calculate the costs of research and development, management and so on, and then allocate the costs to five years
.
"Pharmaceutical companies should take the initiative to assume social responsibility and keep the profit level within a reasonable range
.
" It is mentioned
in the Notice.
It is undeniable that in view of the failure of P drug negotiations, if domestic oral drugs can enter medical insurance in the future, they can still have a lot of profit margins and markets, and they may usher in their own spring
.
Now a large number of domestic new crown oral drugs are waiting to be judged, the most famous of which includes Junshi Biologics' VV116
.
This drug is the same as Merck's monupivir as the RdRp inhibitor technology route and has been approved in Uzbekistan for moderate to severe disease
.
Recently, VV116 began another clinical trial
.
On December 19, Junshi Biologics registered a Phase III clinical trial
of VV116 head-to-head compared with Paxlovid for the treatment of mild to moderate COVID-19 virus rebound rate.
Domestic Pioneer Pharmaceuticals and other industries are also doing similar tests
.
Even if the review becomes more difficult, there is still a steady stream of
latecomers.
On December 18, Simcere Pharmaceutical announced that the company cooperated with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Wuhan Institute of Virology to cooperate with the anti-new coronavirus drug SIM0417
The Phase II/III clinical study has completed patient enrollment
.
Zhongsheng Pharmaceutical announced on December 28 that the company's RAY1216, a randomized, double-blind, placebo-controlled phase III clinical study protocol for the treatment of mild and common new crown infection patients, has obtained rapid review approval for clinical trials, and is currently conducting phase III clinical studies
.
Like Paxlovid, the drugs under study are also 3CL protease inhibitors
.
It seems that although the domestic new crown oral medicine has not grabbed the first wave of dividends, it is still in an era of opportunities in the right time and place
.
But Pfizer's case also tells us that only those drugs that grab speed and can really solve clinical needs and have clinical value can come out on top
.
